Randomized double-blind safety comparison of intravenous iron dextran versus iron sucrose in an adult non-hemodialysis outpatient population: A feasibility study
Authors:
- Martha L. LouzadaMLMartha L. Louzada
- Cyrus C. HsiaCHCyrus C. Hsia
- Fatimah Al-AniFAFatimah Al-Ani
- Fiona RalleyFRFiona Ralley
- Anargyros XenocostasAXAnargyros Xenocostas
- Janet MartinJMJanet Martin
- Sarah E. ConnellySCSarah E. Connelly
- Ian H. Chin-YeeICIan H. Chin-Yee
- Leonard MinukLMLeonard Minuk
- Alejandro Lazo-LangnerALAlejandro Lazo-Langner
Open Access
- 11 March 2016
- journal article
- research article
- Published by Springer Nature in BMC Hematology
- Vol. 16 (1) , 1-8
Abstract
Intravenous iron therapy is a treatment option for iron deficient patients who are intolerant to oral iron or where oral iron is ineffective, but with possible adverse effects. Currently, prospective studies comparing different intravenous iron formulations are needed to determine safety and efficacy of these agents. We conducted a prospective, double-blind, randomized controlled trial (RCT) to assess the feasibility of a trial comparing the safety of high molecular weight intravenous iron dextran, Infufer®, with intravenous iron sucrose, Venofer®, in non-hemodialysis adult outpatients. Primary outcome was the occurrence of immediate severe drug reactions. We enrolled 143 patients in a one-year period. Overall, 45/143 (31.5 %) patients (20 iron dextran, 25 iron sucrose) developed 48 infusion reactions (14 immediate, 28 delayed, and 3 both). The risk of an immediate reaction was similar in both groups, 9/73 (12.3 %) iron dextran versus 8/70 (11.4 %) iron sucrose, RR = 0.93 (95 % CI; 0.38 to 2.27). The risk of a delayed reaction was significantly higher in the iron sucrose group 22/70 (31.4 %) versus the iron dextran group 9/73 (12.3 %), RR = 2.55 (95 % CI; 1.26 to 5.15; p = 0.0078). In this limited feasibility study, no major differences in immediate reactions were seen, but a significantly higher number of delayed reactions were seen in the iron sucrose group. Further, under our assumptions and design a full RCT to evaluate the safety of different intravenous iron preparations is not feasible. Future studies should consider modifying the clinical outcomes, utilize multiple centers, and consider other emerging parenteral iron formulations. (ClinicalTrials.gov NCT005936197 January 3, 2008).Keywords
This publication has 20 references indexed in Scilit:
- Comparative rates of adverse events with different formulations of intravenous ironAmerican Journal of Hematology, 2012
- Clinical Use of Intravenous Iron: Administration, Efficacy, and SafetyHematology-American Society Hematology Education Program, 2010
- Intravenous IronNew England Journal of Medicine, 2007
- Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparationsTransfusion Alternatives in Transfusion Medicine, 2007
- Adverse events associated with intravenous iron infusion (low‐molecular‐weight iron dextran and iron sucrose): a systematic reviewTransfusion Alternatives in Transfusion Medicine, 2007
- Is There a Difference between the Allergic Potencies of the Iron Sucrose and Low Molecular Weight Iron Dextran?Renal Failure, 2007
- Prevalence of Iron Deficiency and Iron Deficiency Anemia among Three Populations of Female Military Personnel in the US ArmyJournal of the American College of Nutrition, 2006
- Safety in iron managementAmerican Journal of Kidney Diseases, 2003
- An iron treatment trial in an Aboriginal community: Improving non‐adherenceJournal of Paediatrics and Child Health, 1999
- The safety of intravenous iron dextran in hemodialysis patientsAmerican Journal of Kidney Diseases, 1996